Abstract: Objective To observe whether target therapy can improve the hemodynamic parameters,heart function and exercise tolerance in patients with chronic thromboembolic pulmonary hypertension(CTEPH). Methods Twenty-five CTEPH patients admitted to our hospital from March 2009 to March 2012 were enrolled in this study.Sixteen weeks after they were treated with oral endothelin receptor antagonist(bosentan),phosphodiesterase type-5 inhibitor(silaenafil),prostanoids(iloprost) alone or their combination,their 6-minute walking distance(6MWD),heart function and echocardiogram were reexamined. Results The 6MWD increased from(321±118) m to(351±102) m,the mean pulmonary artery pressure(mPAP) on echocardiogram decreasedfrom(53.96±9.23) mmHg to(46.36±10.95) mmHg,the tricuspid annular plane systolic excursion(TAPSE) increased from(1.3±0.4) cm to(1.4±0.3) cm,the cardiac index decreased from 0.71±0.19 to 0.64±0.19,and the N-terminal pro-brain natriuretic peptide(NTproBNP) level decreased from(1 942.24±880.24) pg/ml to(861.22±378.31) pg/ml in the patients 16 weeks after treatment(P<0.05). Conclusion Target therapy is effective for CTEPH patients and can improve their hemodynamic parameters and exercise tolerance.